Upadacitinib Dosing Recommendation
For an adult patient without contraindications, upadacitinib dosing is disease-specific: 15 mg orally once daily for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis; 15 mg or 30 mg once daily for atopic dermatitis (with 30 mg reserved for inadequate responders to other systemic therapies); 45 mg once daily for 8-12 weeks induction followed by 15 mg or 30 mg once daily maintenance for ulcerative colitis and Crohn's disease.
Disease-Specific Dosing
Rheumatoid Arthritis and Spondyloarthropathies
- Standard dose: 15 mg orally once daily 1, 2, 1
- This dose is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis
- The 15 mg dose demonstrates superior efficacy compared to placebo and methotrexate with a favorable safety profile 3, 4
Atopic Dermatitis
- Initial dose: 15 mg orally once daily 5
- Higher dose option: 30 mg once daily for patients requiring greater efficacy
- The 30 mg dose shows highest efficacy in reducing disease severity but carries increased adverse event risk 5
- Not considered first-line: Should be reserved for patients who have failed other systemic therapies (immunosuppressants, corticosteroids, antimetabolites, biologics) or when these are inadvisable 5
Inflammatory Bowel Disease
- Induction: 45 mg orally once daily for 8-12 weeks 6, 7
- Maintenance: 15 mg or 30 mg once daily 1, 8
- The 30 mg maintenance dose provides an additional 8-10% benefit for endoscopic response and remission in biologic-refractory patients 6
- Extended induction (12-24 weeks) may be considered for inadequate responders, though this is based on limited retrospective data 7
Treatment Duration
Duration is indefinite for chronic inflammatory conditions - upadacitinib is a maintenance therapy, not a time-limited treatment. The decision to continue, reduce dose, or discontinue should be based on:
- Disease activity monitoring: Assess clinical response at 12-16 weeks
- Sustained remission: Consider dose reduction only after achieving sustained low disease activity or remission on background therapy 1, 9
- Safety monitoring: Ongoing assessment for adverse events may necessitate dose adjustment or discontinuation
Dose Adjustments
Renal Impairment
- CrCl ≥30 mL/min: No dose adjustment required 1
- CrCl <30 mL/min: No specific dosage reduction recommended for upadacitinib (unlike tofacitinib and baricitinib) 1
Hepatic Impairment
- Mild to moderate (Child-Pugh A or B): No dose adjustment required
- Severe (Child-Pugh C): Contraindicated - do not use 1
Drug Interactions
- Strong CYP3A4 inhibitors (ketoconazole): Reduce to 15 mg once daily if on higher doses 1
- Strong CYP3A4 inducers (rifampicin): Consider dose increase, though specific guidance is limited 1
Critical Safety Monitoring
Baseline Requirements
- Screen for tuberculosis (TB), hepatitis B and C 5, 2
- Complete blood count with differential
- Liver function tests
- Lipid panel
- Pregnancy test if applicable
Ongoing Monitoring
- CBC with differential: At 4-8 weeks after initiation, then every 3 months 2
- Liver enzymes: At 4 weeks (or per routine management), then every 3 months 5, 2
- Lipids: At 12 weeks, then annually 2
Vaccination Considerations
Administer recombinant zoster vaccine (Shingrix) before initiating therapy - herpes zoster risk is elevated with JAK inhibitors, particularly in older patients and those on higher doses 5, 10. The recombinant vaccine is non-live and safe to give to immunocompromised patients.
Common Pitfalls
Higher Doses Increase Risk Without Proportional Benefit
The 30 mg dose in rheumatoid arthritis and the 45 mg dose beyond induction in IBD are associated with increased serious infections, herpes zoster, and laboratory abnormalities without substantially greater efficacy 5, 11. Use the lowest effective dose.
Age and Cardiovascular Risk
While FDA warnings about cardiovascular events, malignancy, and thrombosis are based primarily on tofacitinib data in older RA patients with cardiovascular risk factors 5, 1, exercise caution in patients ≥65 years with cardiovascular risk factors. The atopic dermatitis population typically has lower baseline risk than the studied RA population 5.
Pregnancy and Contraception
Contraception is mandatory - limited human data exist, and animal studies show teratogenic effects 1. Discontinue 4 weeks before planned conception 1.
Not for Active Serious Infections
Do not initiate during active serious infections, including active TB 1. Complete TB prophylaxis if latent TB is detected before starting upadacitinib.